Implications for post critical illness trial design: sub-phenotyping trajectories of functional recovery among sepsis survivors. by Puthucheary, ZA et al.
1 
 
Implications for post critical illness trial design: sub-phenotyping trajectories of functional 1 
recovery among sepsis survivors 2 
 3 
Zudin A. Puthucheary1,2, Jochen S. Gensichen3,4,11, Aylin S. Cakiroglu5, Richard Cashmore2, 4 
Lara Edbrooke6,10, Christoph Heintze7, Konrad Neumann8, Tobias Wollersheim9, Linda 5 
Denehy6,10 and Konrad F.R. Schmidt3,7,11 6 
 7 
Corresponding author 8 
Dr Zudin Puthucheary, Critical Care and Perioperative Medicine Research Group, 9 
Adult Critical Care Unit, Royal London Hospital, London, E1 1BB, United Kingdom 10 
Email: z.puthucheary@qmul.ac.uk 11 







Patients who survive critical illness suffer from significant physical disability. The impact of 17 
rehabilitation strategies on Health-Related Quality of Life (HRQoL) is inconsistent, with 18 
population heterogeneity cited as one potential confounder. This secondary analysis aimed 19 
to examine trajectories of functional recovery in critically ill patients to delineate sub-20 
phenotypes; examine the distinguishing clinical characteristics between these cohorts and 21 




291 adult sepsis survivors were followed up for 24 months by telephone interviews. Physical 26 
function was assessed using the Physical Component Score (PCS) of the Short Form-36 27 
Questionnaire (SF-36), Activities of Daily Living (ADL) and the Extra Short Musculoskeletal 28 
Function Assessment regarding physical function and disability (XSFMA-F/B). Longitudinal 29 
trajectories were clustered by factor analysis. Logistical regression analyses were applied to 30 
patient characteristics potentially determining cluster allocation. Responsiveness, floor and 31 
ceiling effects and concurrent validity were assessed within clusters. 32 
 33 
Results 34 
159 patients completed 24 months follow-up, presenting overall low PCS-scores. Two 35 
distinct sub-cohorts were identified, exhibiting complete recovery or persistent impairment. 36 
A third sub-cohort could not be classified into either trajectory. Age, education level and 37 
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number of co-morbidities were independent determinants of poor recovery (AUROC 0.743 38 
((95%CI 0.659-0.826); p<0.001). Those with complete recovery trajectories demonstrated 39 
high levels of ceiling effects in Physical Function (15%), Role Physical (45%) and Body Pain 40 
(57%) domains. Those with persistent impairment demonstrated high levels of floor effects 41 
in the same domains: Physical Function (21%), Role Physical (71%) and Bodily Pain (12%). 42 
The Physical Function domain of the SF-36 demonstrated high responsiveness between ICU 43 
discharge and at 6 months was predictive of a trajectory of persistent impairment (AUROC 44 
0.859 (95%CI 0.804-0.914); p<0.001). 45 
 46 
Conclusions 47 
Within sepsis survivors, two distinct recovery trajectories of physical recovery were 48 
demonstrated. Older patient with more co-morbidities and lower educational achievements 49 
were more likely to have a persistent physical impairment trajectory. 50 
In regard to trajectory prediction, the Physical Function score of the SF-36 was more 51 
responsive than the Physical Component Score and could be considered for primary 52 
outcomes. Future trials should consider adaptive trial designs that can deal with non-53 
responders or sub-cohort specific outcome measures more effectively. 54 
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Increasing numbers of patients are successfully surviving critical illness. Unfortunately, 61 
residual functional and/or mental disabilities affect many critical care survivors after 62 
hospital discharge [1, 2]. Despite extensive research into rehabilitation strategies, few 63 
studies have been able to demonstrate a positive effect on this ensuing dysfunction or 64 
improve Health-Related Quality of Life (HRQoL) [3-6]. Given that rehabilitation strategies 65 
have a strong evidence base in other patient populations [7], trial-related methodological 66 
issues have been proposed as a source of influence in this area and examined [8, 9].  67 
Population heterogeneity within the critically ill cohort is one area that may hinder current 68 
outcome analysis. Certain specific patient characteristics have already been identified as 69 
influential in regards to an individuals’ subsequent HRQoL outcome. To date, these include, 70 
age [10], pre-critical illness comorbidity [11], and socioeconomic-status [12]. Severity of 71 
critical illness, Intensive Care Unit (ICU) Length of stay and the effect of within-ICU 72 
physiology remain unclear influences, as does sex [10, 11, 13-16]. If these factors are not 73 
accounted for in trial design, patient stratification, or analysis, outcome data may be 74 
unintentionally skewed. Many of the current outcome assessments for trials in critical care 75 
fail to account for these confounders [15, 17]. Patient reported outcome measures are 76 
increasingly prioritised as endpoints [18-20]. The Physical Component Score (PCS) of the 77 
Short Form-36 Questionnaire (SF-36) is used to demonstrate the physical disability of critical 78 
care survivors [21], and is widely reported in rehabilitation trials.  79 
Several re-analyses have demonstrated sub-phenotypes based on recovery trajectories [9, 80 
15, 22]. How these sub-phenotypes respond to the variety of assessments that measure 81 
HRQoL currently in use is not yet defined. It may be that these assessments, often applied as 82 
outcome measures, have different clinimetric properties within patient sub-populations. 83 
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Understanding this aspect of measurement in addition to recovery trajectories will be 84 
important to future trial design and outcome interpretation. 85 
We performed a secondary analysis of a critical care trial of sepsis survivors using two-year 86 
follow-up data [23]. The aim of this was to i) examine the trajectories of functional recovery 87 
in critically ill patients using an agnostic approach to delineate patient sub-phenotypes; ii) 88 
examine the distinguishing clinical characteristics between these cohorts and iii) assess the 89 
differences in clinimetric properties of assessment tools of physical function between 90 
cohorts.  91 
 92 
Methods 93 
The patient cohort comprised of those recruited to a randomised control trial conducted 94 
between February 2011 and December 2015 evaluating a primary care-based sepsis 95 
aftercare intervention [23] [24]. Two hundred and ninety-one adult survivors of sepsis were 96 
recruited from nine centres across Germany. Trial design, methodology and outcomes are 97 
described in detail in the original manuscript [23, 25]. Briefly, trained study nurses collected 98 
baseline data at in-person interviews while participants were still hospitalized. Follow-up 99 
data pertaining to HRQoL and physical function were collected at 6 months, 12 months and 100 
24 months by telephone interviews. Those instruments specific to this analysis were the 101 
Physical Component Score (PCS) of the SF-36 [26], three of its four subdomains (Physical 102 
Function, Role Physical and Body Pain), activities of daily living (ADL) and the Extra Short 103 
Musculoskeletal Function Assessment regarding physical function and disability (XSFMA-104 
F/B) [27]. This extra short questionnaire is derived from the 101-item Musculoskeletal 105 
Function Assessment (MFA) by Engelberg and al. to assess functional status from the 106 
patient's perspective [28]. It has been mainly used in Germany for patients following 107 
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orthopaedic surgery [27]. Functional outcome data were also analysed for sub-phenotype 108 
concurrent validity and clinimetric properties. Both randomisation groups were included 109 
into analyses, as no effects of the intervention were shown regarding functional or HRQoL 110 
outcomes [23]. Only those with complete data sets (all four time points) were used in this 111 
analysis. 112 
Education and Family status classifications are shown in Additional Table 1 and addressed 113 
domains of instruments used in Additional Table 1.1. 114 
 115 
Trajectory Projection cluster analysis 116 
Groups of longitudinal trajectories of Physical Component Scores of the SF-36 (the most 117 
commonly reported 6-month HRQoL outcome measure [3, 6, 29-34]) were clustered using 118 
the R-package TRAJ [35-37] and applied. Briefly, this package implements a 3-step 119 
procedure [36]. Firstly, 24 summary measures (available in Additional Table 2) are calculated 120 
that measure the features of trajectories. These measures were then analysed using factor 121 
analysis to select those that best describe the main features of trajectories. Lastly, using 122 
these factors the trajectories were clustered. 123 
 124 
General statistical analysis 125 
Continuous data were assessed for normality using D’Agostino and Pearson omnibus 126 
normality tests and analysed using paired two-tailed Student’s t-test or Mann Whitney U 127 
test as appropriate. Normally distributed data were described using mean (95% Confidence 128 
Interval) and non-normally distributed data as median (interquartile range). Categorical 129 
variables were analysed by χ2 testing. Multivariable and univariable logistic regression 130 
analyses were applied to variables potentially determining cluster allocation (dependent 131 
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variable) Unclustered participants were not used in the logistical analysis, and a multinomial 132 
regression performed as a sensitivity analysis. Independent variables were determined as 133 
characteristics (Table 1), with a univariable screening threshold set at p<0.10. Significance 134 
for all other tests was set at p<0.05. Area under the Receiver-Operator-Curve was used to 135 
test the predictive capacity of early ICU discharge and 6 months assessments for persistent 136 
functional impairment. 137 
 138 
Floor and Ceiling Effects 139 
Scores at their lowest point are defined as 'floor effects' and a 'ceiling effect' occurs where 140 
patients 'may show no improvement in function if a functional scale is not able to assess 141 
high level instrumental ADLs (a ceiling effect) [38, 39]. Floor and ceiling effects render a 142 
measure unable to discriminate between participants at either extreme of the scale. This 143 
negatively affects measurement properties, including sample size requirements. Reducing 144 
these effects by choice of the right measure can therefore improve study efficiency 145 
[40].Floor effects were calculated as the percentage of participants scoring the worst 146 
possible score for the measure. Ceiling effects were calculated as the percentage of 147 
participants scoring the best possible score for the measure. Components of the SF-36 were 148 
examined at the differing time points for floor and ceiling effects, for the cohort as a whole 149 
and for the individual clusters. Floor and ceiling effects were considered relevant if >15% of 150 
the participants had the highest or lowest score respectively [41]. 151 
 152 
Concurrent validity 153 
Concurrent validity is a measure of how well a test compares to a gold standard (such as the 154 
PCS) [38] and its substitutability. Therefore, it is a component of criterion validity, an 155 
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estimate of accuracy based on an external criterion [42]. Coefficient of Determination from 156 
regression between parameters was used to measure concurrent validity (the degree to 157 
which a test can be used as a substitute measure for the gold standard) between the PCS 158 
and PF of the SF-36, ADLs and XSFMA-F/B. All coefficients were interpreted as: little (0.00-159 
0.25), fair (0.25-0.50), moderate (0.50-0.75) and excellent association (0.75-1.0) [43]. 160 
 161 
Responsiveness 162 
Responsiveness is a measure of sensitivity to change and discriminatory properties (the 163 
ability to detect clinically relevant change in health status over time), and part of the 164 
COSMIN checklist (COnsensus‐based Standards for the selection of health 165 
Measurement)[42, 44, 45]. Change in scores from hospital discharge to 24 months were 166 
assessed using paired t-tests and data represented as mean difference and 95% CI [43]. 167 
Responsiveness of each test to time/recovery post critical illness was calculated using the 168 
effect size index, calculated as the mean change score divided by the baseline pooled 169 
standard deviation [38, 46]. Changes were interpreted according to Cohen’s d effect size as 170 
small (0.2 to 0.49), moderate (0.5 to 0.79) and large (>0.80) [47, 48]. 171 
 172 
Results 173 
Of the original 291 participants recruited, 24-month follow-up data was collected on 186 174 
participants (41 lost to follow-up, 64 died <24 months). Complete data was available on 159 175 
participants who were included in the final analyses. Those with incomplete follow-up were 176 
not included. When compared, those who died were older, had a longer length of stay and 177 
more co-morbidities, all of which is not unexpected (see Additional Table 3). 178 
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PCS of the SF-36 for critically ill participants were reduced relative to population norms at 179 
ICU discharge and remained low at 24 months (Figure 1A).  180 
 181 
(insert Figure 1) 182 
 183 
Trajectory Clustering 184 
Trajectory projection analysis identified two distinct sub-cohorts: one cohort exhibited a 185 
faster and more complete recovery trajectory defined as within one standard deviation of 186 
population norms (n=61). A second cohort exhibited more persistent functional impairment 187 
(n=76) (Figure 1B). The remaining 22 participants were not classified into either cohort, as 188 
no clear trajectory was seen (Additional Figure 2). The differing characteristics of the 189 
cohorts are shown in Table 1. 190 
 191 
(insert Table 1) 192 
 193 
The complete recovery cohort, were on average younger (56 years (IQR 43-70) vs. 65 years 194 
(IQR 54-72), P=0.002, Figure 2A), with higher education levels (5(4-8) vs. 5(3-5), P= 0.039, 195 
Figure 2B), more likely to be unmarried (Figure 2D) and had a lower BMI (25.8(22-29) vs. 196 
27.8(24-32), P=0.006. 197 
 198 
(insert Figure 2) 199 
 200 
A multivariable logistic regression analysis demonstrated age, education level and number 201 
of co-morbidities as independent determinants of poor recovery (Additional Table 4). A 202 
10 
 
model with these factors had a predictive capacity with an AUROC of 0.743 ((95%CI 0.659-203 
0.826); p<0.001; Additional Figure 1) for cohort membership and was not over-fitted 204 
(Hosmer-Lemeshow statistic 8.456, p=0.390). Neither Body Mass Index nor Family Status at 205 
discharge were significant within this analysis. In a multinomial analysis, age and education 206 
remained independent determinants of recovery with the addition of Body Mass Index 207 
(Additional table 4.1) but not number of co-morbidities (p=0.051). No determinants were 208 
independently associated with the unclustered trajectory (see Additional Table 4.2). 209 
 210 
Floor and Ceiling effects  211 
At 24-month follow up, participants in the completed recovery cohort demonstrated 212 
relevant ceiling effects within the Physical Function (15%), Role Physical (45%) and Body 213 
Pain (57%) domains of the SF-36. In contrast, those participants with persistent functional 214 
disability demonstrated the reverse, with relevant floor effects within Physical Function 215 
(21%), Role Physical (71%) but not Bodily Pain (12%), see Table 2 and Figure 3. These results 216 
were relatively consistent over the preceding 24 months (Additional Tables 5A and B). Floor 217 
scores at ICU discharge were only moderately associated with a persistent functional 218 
impairment trajectory (PF (AUROC 0.609 (95%CI 0.537-0.681); p=0.002) and RP (AUROC 219 
0.653 (95%CI 0.584-0.721); p<0.001)). However, floor scores at 6 months were good 220 
predictors of a trajectory of persistent functional impairment (RP (AUROC 0.586 (95%CI 221 
0.513-0.658); p=0.014)), and PF (AUROC 0.938 (95%CI 0.901- 0.974); p<0.001)). 222 
 223 




Concurrent validity 226 
Those participants with complete recovery demonstrated moderate to excellent concurrent 227 
validity between SF-36 PCS and both XSFMA-B AND XSFMA-F, and fair validity with ADL 228 
scores. Those participants with persistent disability demonstrated moderate concurrent 229 
validity between SF-36 PCS and both XSFMA-B AND XSFMA-F, and fair validity with ADL 230 
scores (Table 3). 231 
 232 
(insert Table 3) 233 
 234 
Responsiveness 235 
High responsiveness was seen in the complete recovery group at all time points in the 236 
Physical Component Score (>1.0) and most notably in the Physical Function domain (>1.6), 237 
with a similar pattern seen in Role Physical. However, this was not seen in the persistent 238 
impairment cohort, where Physical Function and Role Physical achieved only moderate 239 
responsiveness at 6 months (>0.7). All other scores and time points demonstrated at best 240 
limited responsiveness (Table 4). PF responsiveness between ICU discharge and 6 months 241 
was predictive of a trajectory of persistent impairment (AUROC 0.859 (95%CI 0.804-0.914); 242 
p<0.001). 243 
 244 





This post-hoc study examines the trajectories of functional impairment in cohorts of sepsis 248 
survivors regarding sub-phenotypes and specific clinical characteristics. 249 
Two distinct sub-cohorts were identified: one of faster and more complete recovery and the 250 
other of slower recovery with more persistent functional impairment. A third sub-cohort 251 
could not be classified into either trajectory. This study also demonstrates that the older 252 
patient with more co-morbidities and with lower educational achievements is more likely to 253 
have a trajectory associated with persistent functional impairment. Importantly the 254 
measures used exhibit very different clinimetric properties when HRQoL is measured 255 
longitudinally in different sub-cohorts. Those with good recovery have significant ceiling 256 
effects with the physical components of the SF-36 questionnaire and demonstrate high 257 
responsiveness over time. The reverse is seen in those with persistent impaired HRQoL, 258 
where significant floor effects are seen and limited responsiveness. Moderate to excellent 259 
concurrent validity was obtained across tests of HRQoL and physical function. The Physical 260 
Function (PF) score had the highest degrees of responsiveness across sub-cohorts and time 261 
and was predictive of a trajectory of persistent impairment when measured up to 6 months. 262 
Scoring the lowest value of PF at 6 months also was predictive of poorer outcomes at 24 263 
months, which might be an indicator for the necessity to develop individualized 264 
rehabilitation programs for every patient. 265 
 266 
Individual Patient Characteristics 267 
These data reiterate the role that age and multiple chronic diseases have on recovery of 268 
physical HRQoL post critical illness. Interestingly, the individual odds ratios for these factors 269 
are lower than that of educational status. This may be because educational status is 270 
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reflective of poorly quantified and measured socioeconomic factors as well as individual 271 
coping abilities that are essential for the rehabilitation process [49]. However, chronological 272 
age is increasingly recognised as less accurate in terms of function relative to physiological 273 
age in the elderly [50], and the Charlston Co-morbidity Index was not designed or validated 274 
for the critical care survivor population. Ultimately these data demonstrate that 275 
stratification (or population enrichment strategies) on one or two of these variables are 276 
unlikely to be sufficient. We have begun to understand how frailty, cognitive deficits [51], 277 
comorbidities [9], age and ICU length of stay [22, 52] interact to result in post-critical illness 278 
disability, and our data confirm these findings but also suggest that these factors need to be 279 
integrated with socioeconomic data for improved identification of sub-phenotypes. The 280 
impact of social isolation is reported in other chronic diseases and needs more attention in 281 
critical illness populations [12]. 282 
 283 
Physical Function and Health Related Quality of Life outcome measures 284 
The use of HRQoL and patient reported outcome measures are important and increasingly 285 
mandated, and the data reported here may help to focus the field on the appropriateness of 286 
the specific domains of the SF-36 to measure HRQoL in different subpopulations with 287 
different illness trajectories. The PCS has been used as a primary outcome measure in 288 
rehabilitation trials [6, 29], in nutrition intervention trials [53] and is in general the most 289 
commonly reported 6-month HRQoL outcome measure [3, 6, 29-34]. The PF subscore has 290 
also been used as a primary outcome measure in critical illness [54]. Fundamentally, 291 
selection of an outcome measure assumes that the intervention is suitably designed with 292 
the primary outcome in mind. When evaluating rehabilitation trials if the primary outcome 293 
of a trial is health-related quality of life, then using the summative score (PCS, incorporating 294 
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all subdomains to reflect overall health-related quality of life) would be appropriate. In 295 
contrast, if the primary outcome is physical function, then it may be more appropriate to 296 
select the Physical Function subdomain as the measure used to evaluate the trial. It should 297 
be noted that HRQoL outcome measures have often been shown to not be sensitive enough 298 
to be affected by the biological efficacy of current post ICU interventions [63]. 299 
 300 
To date, little exploration of the most sensitive component of the SF-36 to use in trials of 301 
rehabilitation interventions has been conducted [55]. Physical and mental health factors 302 
account for 80-85% of the reliable variance in the 8 scales of the SF-36 [56]. A scoring 303 
assumption central to the summative scores (i.e. PCS and MCS) is that score aggregation 304 
could occur without score standardization or item weighing [57]. Our data challenge this 305 
assumption: in the presence of significant heterogeneity of physical HRQoL and disability 306 
post critical illness, individual domains are more appropriate outcome measures than 307 
summative scores for physical rehabilitation trials, given the responsiveness and predictive 308 
outcomes seen across patient sub-phenotypes. Of note the PF score has long been known to 309 
be the most valid scale for physical activity [58] and our data demonstrate that aggregating 310 
PF with the other components of the PCS decreases the clinimetric strength. The PF domain 311 
includes questions related to activities needed for daily living rather than also including 312 
return to work and questions about pain as found in the PCS. The PF domain includes 313 
several advanced mobility measures, independent activities of daily living, some activities of 314 
daily living as well as several items of the XSFMA, which may explain the concurrent validity 315 
findings, as this may be better viewed as construct validity. It may be that in the post critical 316 
illness population there is a more specific objective perception of physical function (the PF 317 
score, comprising of 10 questions), resulting in higher responsiveness than broader 318 
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subjective limitations in daily life (the RP score, comprising of 4 questions, or General Health 319 
comprising of 5 questions) or perception of pain (the BP score, comprising of 2 questions). 320 
However, the PF score also has significant ceiling effects (in those that recover) and floor 321 
effects (in those with persistent disability), suggesting the need for concurrent 322 
measurement of other more specific outcome measures such as the XSFMA-F which showed 323 
excellent validity with the SF-36 PF to address this. Notably, using the PF domain score at 6 324 
months can predict poorer physical HRQoL outcomes and may help to guide further 325 
community or out-patient based individualised rehabilitation treatment. 326 
 327 
Strengths and limitations 328 
A major strength of these analyses are the data themselves- few long-term cohort studies 329 
exist with serial contemporaneous HRQoL and physical function data to allow detailed 330 
clinimetric testing of outcome measures. The cohort size was large relative to other long 331 
term cohort studies with serial contemporaneous HRQoL and physical function data. It is 332 
widely accepted, and accords with common sense, that the imputation of missing data on 333 
HRQoL for a deceased participant is inappropriate [59]. This is in keeping with approaches 334 
applied to randomised controlled trials [60] and is an approach used by others (with specific 335 
expertise in imputation) within the field of rehabilitation [59, 61]. This would also be 336 
consistent with analyses applied to this cohort which we have recently published [24]. 337 
Those patients who died were older, had a longer length of stay and more co-morbidities, 338 
and  a 2-year follow-up period may not be appropriate for this sub-cohort. 339 
 340 
A fundamental issue with clinimetric property assessment of summed scores like the PCS is 341 
the content overlap [57], as the used subscores are in part textual identical with the 342 
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summed score and there also was a high contentual intersection with the XSFMA-F/B and 343 
ADL scores. This is difficult to overcome, as the PCS is near ubiquitous in its use for 344 
measurement of physical HRQoL. The use of trajectory clustering techniques decreased the 345 
risk of bias relative to a researcher driven approach. The retrospective nature of this 346 
analysis mandates that the conclusions are tested prospectively. Trajectory cluster validity is 347 
limited by 22 (13.8%) of patients being not classifiable and understanding why these 348 
patients have unclear trajectories requires prospective analysis, using a mixed-349 
methods approach. The XSFMA F/B scores have only been validated in German, limiting its 350 
use, though it was derived from the English SFMA [62]. Other tools such as the Functional 351 
Status Score for the Intensive Care Unit (FSS_ICU) or the Physical Function in Intensive Care 352 
Test scored (PFIT-s) may be of use, having been validated in several countries and languages 353 
[35]. While the focus of this manuscript has been on self-reported outcome measures, the 354 
subjective nature of these does constitute a limitation and comparative assessment with 355 
objective measures in sub-cohorts may be warranted. 356 
 357 
Implications for outcome selection and trial design 358 
As HRQoL outcome measures have often shown lack of sensitivity in post ICU interventions 359 
[63], our data offers two potential methodological solutions: Firstly, the described sub 360 
population characteristics, especially those relating to education could be used as 361 
population refinement tools for trials, either as inclusion/ exclusion criteria or for 362 
differential outcome measures set a priori. This may or may not be feasible where large 363 
samples are required, though a differential effect between sub populations has been used in 364 
phase II trials (NCT02358512). Secondly an adaptive trial design could use a) the presence of 365 
a floor effect as a predictor of a poor trajectory (i.e. a non-responder) in a multi-arm, multi-366 
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stage fashion that explores treatments, doses with an option to exclude non-responders 367 
[64]; b) the characteristics (e.g. education or socioeconomic status) for population 368 
enrichment that narrow down recruitment to those who are likely to benefit most [65] or c) 369 
the PF score in conjunction with other markers e.g. CRP (as a marker of persistent 370 
inflammation) in a biomarker adaptive design [66] to stratify patients. Lack of data to inform 371 
adaptive trial design remains one of the barriers to their use and this study offers 372 
suggestions to overcome this [67]. 373 
Both subscore and summary score responsiveness varied over time in both cohorts, with a 374 
plateau seen after 6 months. These data imply that physical HRQoL endpoints may be more 375 
suited to earlier timepoints (e.g. 3 and 6 months), and other, more responsive endpoints are 376 
needed at 1-2 years such as measures of disability. 377 
 378 
Conclusion 379 
Within sepsis survivors, two distinct recovery trajectories of physical recovery could be 380 
demonstrated. Older patient with more co-morbidities and lower educational achievements 381 
are more likely to have a trajectory associated with persistent physical impairment. In 382 
regard to trajectory prediction, the Physical Function score of the SF-36 was more 383 
responsive than the Physical Component Score of the SF-36 and could be considered for 384 
primary outcomes. Future trials should consider adaptive trial designs that can deal with 385 
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Figure 1: Trajectory of physical recovery over 24 months 472 
indicated by the Physical Component Score (PCS) of the SF-36, mean (95%CI) of 473 
(A) all patients and (B) two sub cohorts: green line: complete recovery, red line: persistent 474 
impairment. 475 
*represents P<0.05 for unpaired two-tailed Student’s T-tests. Dotted line represents 476 
population norms. 477 
 478 
Figure 2: Distribution of characteristics of both cohorts 479 
For each figure, red columns represent the persistent impairment cohort, green columns 480 
represent the complete recovery cohort, broken down by A: Age; B: Education Status; C: 481 
number of co-morbidities; D: Family Status. 482 
 483 
Figure 3: SF-36 components floor and ceiling effects 484 
Red columns represent the persistent impairment cohort, and green the completed 485 
recovery cohort, both at 24-month. PF=Physical Function; RP=Role Physical; BP=Bodily Pain; 486 
GH=General Health. 487 




Table 1: Baseline characteristics of different cohorts 








n 76  61  22  
 
Age (y) 65 (54.3-72)  56 (43-70)  63 (52-69.3)  P=0.002* 
Male Sex (n)# 47 (61.8%)  44 (72.1%)  16 (72.7%)  P=0.205 
ICULOS 23.0 (12.8-39.5) 2 19 (10.0-31.0) 6 40.5 (15.3-48.3) 2 P=0.207 
MV(d) 9 (2-20) 1 6 (2-22) 2 10 (4-29) 3 P=0.746 
CCI 3 (1-5.8)  3 (1-5) 1 2.5 (1.8-6)  P=0.246 
RRT (d) 0 (0-0.75)  0 (0-2.5) 3 0 (0-2.5)  P=0.650 
Tracheostomy (n)# 20 (26.3%) 21 18 (29.5%) 13 11 (50%) 3 P=0.678 
Intervention group (n)# 38 (50%)  38 (62.2%)  11(50%)  P=0.150 
Educationǂ$ 5 (1-9)  5 (2-9)  5 (2-9)  P=0.039* 
BMI 27.8 (24.4-32.5)  25.8 (22.6-29.1) 1 26.7 (23-30) 2 P=0.006* 
Family Statusǂ$ 2 (1-6) 1 2(1-6)  2(1-4) 1 P=0.021* 
No. of ICD diagnoses 
at discharge 
9 (6-15)  9 (5-11)  8 (6-15.8)  P=0.077 
Data are shown as medians (interquartile ranges), except for percentages and mode (range). P-values represent Mann Whitney U tests 
between persistent impairment and complete recovery, except for #=Chi-Squared test. ICULOS= Intensive Care length of stay (days), 
MV(d)=Period of mechanical ventilation (days), CCI=Charlston Co-morbidity Index, RRT(d)=Renal Replacement Therapy (days), NA=not 
available.  
$Indicated mode (range) with significance taken to be P<0.05, *represents p<0.05, ǂCategories shown in Additional Table 1.
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Data are shown as numbers of patients with percentages. Data of unclustered group (n=22) 
not shown (raw data shown in Additional Figure 2). PF= Physical Function; RP=Role Physical; 
BP=Bodily Pain; GH= General Health. XSFMA-F= Extra Short Form Musculoskeletal Function 
Assessment regarding physical function (F) 




















PF 16 (10) 9 (6) 0 (0) 9 (15)* 16 (21)* 0 (0) 
RP 71 (45)* 35(22)* 9 (15)* 27 (45)* 54 (71)* 3 (4.0) 
BP 11 (7) 52(33)* 1 (2) 35 (57)* 9 (12) 7 (9.2) 
GH 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
XSFMA-F 29(18)* 0(0) 29 (46) 0(0) 0(0) 0(0) 
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Data shown as coefficients of determination at 24 months after ICU discharge. 
PCS=Physical Component Score of the SF-36, PF=Physical Function subscore, XSFMA-F/B=Extra Short Form Musculoskeletal Function 






 All Complete recovery Persistent impairment 
PCS PF XSFMA-F XSFMA-B ADL PCS PF XSFMA-F XSFMA-B ADL PCS PF XSFMA-F XSFMA-B ADL 
PCS  0.87 -0.80 -0.75 -0.61  0.82 -0.71 -0.60 -0.42  0.60 -0.62 -0.55 -0.44 
PF 0.87  -0.89 -0.82 -0.73 0.82  -0.81 -0.65 -0.61 0.60  -0.81 -0.71 -0.62 
XSFMA- F -0.80 -0.89  0.91 0.84 -0.71 -0.81  0.81 0.58 -0.62 -0.81  0.84 0.78 
XSFMA- B -0.75 -0.82 0.91  0.79 -0.60 -0.65 0.81  0.41 -0.55 -0.71 0.84  0.71 
ADL -0.61 -0.73 0.84 0.79  -0.42 -0.61 0.58 0.41  -0.44 -0.62 0.78 0.71  
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Table 4: Responsiveness of physical function scores at 6, 12 and 24 months post ICU 
discharge. 
 All Complete Recovery Persistent impairment 
Month 6 12 24 6 12 24 6 12 24 
PCS 0.36 0.70 0.47 1.00 1.44 1.14 0.01 0.25 0.15 
PF 1.02 0.88 0.50 1.75 2.05 1.63 0.71 0.42 0.37 
RP 0.68 0.34 0.31 0.73 1.07 1.16 0.70 0.07 0.03 
BP 0.15 0.34 0.03 0.19 0.46 0.38 0.11 0.30 0.31 
XSFMA-F  0.39 0.28  0.42 0.33  0.40 0.27 
XSFMA-B 0.43 0.34 0.39 0.51 0.46 0.27 
ADL 0.28 0.18 0.19 0.05 0.35 0.24 
 
Responsiveness was measured using Cohens ‘d, with changes interpreted as minimal (0.0 to 
0.2, dark grey) small (0.2 to 0.49, grey), moderate (0.5 to 0.79, yellow) and large (>0.80, 





Additional file 1 
- Additional file 1.docx 
- Additional Table 1: Categories of Educational Level and Family Status 
- VT=Vocational Training 
- GSCE=General Certificate of Secondary Education 
- Additional Table 1.1: Addressed domains of used questionnaires 
 
Additional file 2 
- Additional file 2.docx 
- Additional Table 2: Summary measures for Trajectory Projection  
- eMethods of use of trajectory projection 
 
Additional file 3 
- Additional file 3.docx 
- Additional Table 3: Baseline characteristics of the whole cohort and the 24 months 
follow-up cohort 
- Values shown as medians and interquartile range [IQR] except for $representing 
mode (range). P-values represent two-tailed Mann-Whitney U-tests, except for 
#=Chi-Squared test. ICULOS= Intensive Care length of stay. MV (d)=period of 
mechanical ventilation (days), CCI=Charlston Co-morbidity Index, RRT(d)=Renal 
Replacement Therapy (days), PCS=Physical Component Score of the SF-36, MCS 
=Mental Component Score recall 3 months prior to critical illness. XSFMA F/B= Extra 
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Short Musculoskeletal Function Assessment regarding Physical Function and 
Disability, 3m recall=recall 3 months prior to critical illness. NA=Not available, 
*Categories shown in Additional Table 1 
- 147 patients without MV, 11 patients without available data, 2209 patients without 
RRT, 5 patients without available data 
 
- Additional Table 3.1: Baseline characteristics of the whole cohort split by loss to 
follow-up and death. 
- Values shown as medians and interquartile range [IQR] except for $representing 
mode (range). ICULOS= Intensive Care length of stay. MV (d)=period of mechanical 
ventilation (days), CCI=Charlston Co-morbidity Index, RRT(d)=Renal Replacement 
Therapy (days), PCS=Physical Component Score of the SF-36, MCS =Mental 
Component Score recall 3 months prior to critical illness. XSFMA F/B= Extra Short 
Musculoskeletal Function Assessment regarding Physical Function and Disability, 3m 
recall=recall 3 months prior to critical illness. NA=Not available, *Categories shown 
in Table S1 
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Additional file 4 
- Additional file 4.docx 
- Additional Table 4: Bivariable and multivariate logistic regression analysis of cohort 
membership characteristics 
- Dependent variable: Allocation to persistent impairment cohort vs. complete 
recovery cohort. ICD=International Classification of Disease; ICULOS= Intensive Care 
Unit Length of Stay. * represents p<0.05 
 
- Additional Table 4.1: Multinomial regression for the persistent impairment group, 
using the full recovery as the reference group. ICD=International Classification of 
Disease; ICULOS= Intensive Care Unit Length of Stay; * represents p<0.05 
 
- Additional Table 4.2: Multinomial regression for the unclustered group, using the full 
recovery as the reference group. ICD=International Classification of Disease; ICULOS= 
Intensive Care Unit Length of Stay; * represents p<0.05 
 
Additional file 5 
- Additional file 5.docx 
- Additional Tables 5A and B: Ceiling and floor effects 
- Data are shown as n(%) over time for SF-36 components in patients with a persistent 
impairment trajectory (n=76) and in patients with a completed recovery trajectory 
(n=61) (Table 5A: only patients with completed recovery). PF= Physical Function; RP= 
Role Physical, BP=Bodily Pain, GH= General Health, XSFMA-F= Extra Short Form 
Musculoskeletal Function Assessment regarding physical function (F) 
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*represents a value of >15% denoting relevant effect. % may not=100 due to 
rounding effects. 
 
Additional file 6 
- Additional file 6.png 
- Additional Figure 1: Area under receiver operating characteristic curve (AUROC) 
- Logistic regression of predictors of cluster allocation 
 
Additional file 7 
- Additional file 7.png 
- Additional Figure 2: Trajectories of unclustered patients (n=22) 
- Data points are means of the SF-36 Physical Component Score (PCS) over 24 months 
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